Related Experiment Video
Updated: Nov 3, 2025
09:40
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
2.9K
Ubiquitin-proteasome System Is a Promising Target for Killing Cisplatin-resistant Bladder Cancer Cells
Kazuki Okubo1, Makoto Isono1, Takako Asano1
1Department of Urology, National Defense Medical College, Tokorozawa, Japan.
Anticancer Research
|June 4, 2021
Summary
Targeting the ubiquitin-proteasome system (UPS) may overcome cisplatin resistance in bladder cancer. UPS-targeting drugs showed increased efficacy in resistant cells, suggesting a new therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The ubiquitin-proteasome system (UPS) is implicated in cancer drug resistance.
- Understanding UPS activation in bladder cancer is crucial for developing new treatments.
Purpose of the Study:
- To investigate the link between UPS activation and cisplatin resistance in bladder cancer cells.
- To evaluate the effectiveness of UPS-targeting drugs in overcoming cisplatin resistance.
Main Methods:
- Established cisplatin-resistant bladder cancer cell lines (J82-cisR, T24-cisR).
- Assessed UPS activation status in resistant versus parental cells.
- Tested the efficacy of UPS inhibitors (MLN7243, oprozomib, ixazomib, RTS-V5).
Main Results:
- UPS was significantly activated in cisplatin-resistant bladder cancer cells.
- UPS inhibitors demonstrated enhanced efficacy in inducing apoptosis and inhibiting growth in resistant cells.
- UPS inhibitors triggered endoplasmic reticulum stress at lower concentrations in resistant cells.
Conclusions:
- Targeting the ubiquitin-proteasome system presents a promising therapeutic strategy for cisplatin-resistant bladder cancer.
- UPS inhibition may sensitize resistant bladder cancer cells to treatment.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.0K
02:56Treatment Resistant Cancers
3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
01:13The Proteasome
1.3K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.3K
02:18The Proteasome
9.3K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
9.3K
02:50Combination Therapies and Personalized Medicine
5.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.4K